Gubra – Presentation of Phase 1 Topline Results on ABBV-295 (Recording)
In connection with AbbVie reporting positive topline results from a Phase 1 trial for ABBV-295, Gubra’s out-licensed long-acting amylin analogue, we hosted a live event with CFO Kristian Borbos and IR & Strategy Lead Emma Jappe Lange from Gubra.
In addition to a presentation of the study data and findings, the Q&A session provided insights into how the results benchmark against Eli Lilly’s Elorantide, currently seen as the leading reference in the field, as well as further perspectives on dose dependency and other potential differentiators.
Watch the event here:
Disclaimer: HC Andersen Capital receives payment from Gubra for a Digital IR/Corporate Visibility subscription agreement. Michael Friis at 15.09 , d. 10-03-2026.
Sisäänkirjautuminen vaadittu
Tämä sisältö on näkyvissä vain sisäänkirjautuneille käyttäjille